share_log

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer REED JOHN C

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer REED JOHN C

強生 | 4：持股變動聲明-高管 REED JOHN C
美股sec公告 ·  05/03 16:37
Moomoo AI 已提取核心訊息
On May 1, 2024, John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, completed a stock transaction involving the company's common stock. Reed executed a sale of 10,984 shares at a price of $144.59 per share, resulting in a total transaction value of $1,588,176.56. Prior to this sale, Reed acquired 22,255 shares through the exercise of derivative securities at no cost. Following these transactions, Reed's direct holdings in Johnson & Johnson common stock amounted to 11,577 shares.
On May 1, 2024, John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, completed a stock transaction involving the company's common stock. Reed executed a sale of 10,984 shares at a price of $144.59 per share, resulting in a total transaction value of $1,588,176.56. Prior to this sale, Reed acquired 22,255 shares through the exercise of derivative securities at no cost. Following these transactions, Reed's direct holdings in Johnson & Johnson common stock amounted to 11,577 shares.
2024年5月1日，強生公司創新醫學研發執行副總裁約翰·裏德完成了一項涉及公司普通股的股票交易。裏德以每股144.59美元的價格出售了10,984股股票，總交易價值爲1,588,176.56美元。在此次出售之前，裏德通過行使衍生證券免費收購了22,255股股票。這些交易之後，裏德直接持有的強生普通股爲11,577股。
2024年5月1日，強生公司創新醫學研發執行副總裁約翰·裏德完成了一項涉及公司普通股的股票交易。裏德以每股144.59美元的價格出售了10,984股股票，總交易價值爲1,588,176.56美元。在此次出售之前，裏德通過行使衍生證券免費收購了22,255股股票。這些交易之後，裏德直接持有的強生普通股爲11,577股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息